Dr. Joseph Lombardi Co-Chairs International Aortic Summit

lombardi_confJoseph V. Lombardi, MD, Head of the Division of Vascular and Endovascular Surgery at Cooper University Health Care, was congress co-chairman of this year’s International Aortic Summit (IAS), held February 11-13, 2015, in Aruba.

The Summit assembled top leaders in the fields of vascular and endovascular surgery to present and discuss the latest advances in aortic surgery (both open and endovascular techniques). “Aside from a tremendous venue for our faculty and their families, there was an tremendous amount of sophisticated discussion on all forms of aortic surgery by the leaders in our field,” Dr. Lombardi said.

The IAS also featured 15 scholarships for vascular fellows who presented their work along with the faculty. “The educational experience for the fellows, as they presented their work in tandem with invited faculty, cannot be overstated,” said Dr. Lombardi. “Our mission of education and improving care for all patients with aortic pathology underscores the true essence of the IAS.” The IAS 2015 is a comprehensive educational experience open to all surgeons, cardiologists, radiologists, fellows, residents, medical students, nurse practitioners and physician assistants designed to present the latest advances in aor
tic surgery.

Posted in Announcements, Press Releases0 Comments

Latest Issue of Vascular Vitality Now Available

vascvit111Vascular Vitality magazine is an educational resource produced by the Cooper Vascular Surgery team to provide you with tools that will guide you and educate you about the various vascular conditions. Check out our latest issue of Vascular Vitality.

Posted in Press Releases0 Comments

Cooper Participates in Clinical Trial for Patients With Emphysema

Physicians at Cooper University Health Care are taking part in a clinical trial to test the effectiveness of a less invasive treatment for patients with severe emphysema. Cooper is one of about 24 sites participating in the EMPROVE clinical trial in the United States.

Wissam Abouzgheib, MD, Director, Section of Interventional Pulmonology, Division of Pulmonary Medicine, is leading Cooper’s participation in the EMPROVE trial. The trial will specifically evaluate the safety and efficacy of endobronchial valves – small implantable medical devices – for patients with severe emphysema. Currently, these patients have limited therapeutic options or being evaluated for lung transplant or volume reduction surgery, which removes part of the poorly functioning areas of the lung.

“Emphysema is a disease of the lungs that can make breathing difficult,” explained Dr. Abouzgheib. “Lungs are made up of tiny air sacs that absorb the oxygen in the air we breathe. In patients with emphysema, these air sacs are gradually destroyed, which makes it difficult for air to exit the sacs and allows it to become trapped in the most diseased areas of the lung.” The trapped air is what makes “breathing difficult” and also interferes with the function of the healthier areas of the lung

COPD and Emphysema are serious medical conditions that affect millions and are directly linked to smoking. According to the American Lung Association, COPD/Emphysema is the third leading cause of death in America, claiming the lives of 134,676 Americans in 2010.

About the Trial
Through the EMPROVE trial a valve is placed inside the airways of diseased or hyperinflated parts of the lung and redirects the air to healthier parts of the lung, making it easier for the patient to breathe.
The trial is composed of two randomly chosen groups. The treatment group will have valves placed in the lung and be monitored by a doctor. The control group will not have valves placed in the lung, but will also receive care from a trial doctor for the length of the trial. Using this random control method means that the groups will be similar and that the treatments the patients receive can be compared objectively to determine which treatment is best. The randomization is two patients for the valve group to one patient to the control group, increasing the chances to be chosen to receive the valves

Before a patient can enter the EMPROVE trial, a doctor will review their medical history to determine if they are an appropriate candidate. Not all COPD or emphysema patients will benefit from the procedure and there are some significant risks. Potential benefits and risks will be reviewed with all eligible patients by the trial doctor and a member of the trial support team.

Following the procedure, participants will monitored at one month, three months and six months. In addition, patients in the treatment group will receive annual check-ups for five years, while patients in the control group will receive annual check-ups for two years.

If you are a patient suffering from emphysema and would like to know more about the EMPROVE Clinical Trial, please contact Patricia Niblack 856.968.7269.

Posted in Announcements, Press Releases0 Comments

Cooper Opens Its Third Urgent Care Center

urengtcare2Cooper Urgent Care Centers continue to expand their geographic footprint with the opening of a new center in Sicklerville (Winslow Twp.). The center is part of new construction on Cross Keys Road with plenty of retail surrounding it. All three centers are staffed with Emergency Room physicians and have X-ray and laboratory draw capabilities.

Cooper Urgent Care Centers:

500 Cross Keys Road
Sicklerville, NJ 08081
(Winslow Twp.)

2001 Route 70 East
Cherry Hill, NJ 08003

318 S. White Horse Pike
Audubon, NJ 08106

Monday through Friday 8 a.m. to 8 p.m.
Saturday and Sunday 9 p.m. to 5 p.m.

Cherry Hill is open 365 days a year, including 9 p.m. to 5 p.m. on Thanksgiving Day, Christmas Day and New Year’s Day. Audubon and Sicklerville are closed Thanksgiving, Christmas Day and New Year’s Day.


856.874.0134 for all locations.

Posted in Announcements, Newsmakers, Press Releases0 Comments

Cooper Heart Institute Team Performs TAVR Procedure Using Conscious Sedation

Newest Advance in the Evolution of Minimally Invasive Heart Surgery

X-ray cardiovascular systemA team of cardiothoracic surgeons, interventional cardiologists and anesthesiologists at the Cooper Heart Institute recently achieved a medical milestone by performing transcatheter aortic valve replacement, or TAVR, under conscious sedation for the first time. Since then, the team has successfully performed several additional cases using this method.

Cooper is one of a few select heart centers in the region to perform TAVR under conscious sedation, rather than general anesthesia — for those patients who qualify. TAVR, a nonsurgical alternative to open-heart surgery, is an advanced method for the treatment of severe aortic stenosis Cooper was one of the first hospitals in the Delaware Valley to offer the TAVR procedure and recently performed its 200th case.

The TAVR procedure involves feeding an artificial valve by catheter through an artery in the groin or the chest to the heart. Once placed in the correct position, the artificial valve is opened and begins to function.

“This is a game changer,” according to Janah Aji, MD, FACC, Director of the Cooper Cardiac Catheterization Lab, who performed the first conscious-sedation TAVR procedure. “Patients with aortic stenosis are generally elderly and have other health conditions that make them too weak to undergo open-heart surgery. Even general anesthesia may be a significant incremental risk in some patients, thus the potential option of sedation is welcome.” Under conscious sedation, the patient is awake and able to communicate with the physicians during the procedure. The lighter anesthesia can mean less recovery time and a shorter hospital stay.

“We are very excited about this newest milestone,” said Perry J. Weinstock, MD, FACC, Director of the Cooper Heart Institute. “Cooper Heart Institute is a regional leader, continually offering new procedures and advances to our comprehensive adult cardiovascular program that includes a wide-range of non-invasive, invasive, and surgical diagnostic and therapeutic options for patients in South Jersey.” 

An age-related disease that affects approximately 300,000 Americans, aortic stenosis causes chest pain or tightness, fatigue, dizziness, shortness of breath and heart palpitations. The result of calcium deposits in the heart valve that cause it to narrow and stiffen, aortic stenosis makes it hard for the heart to pump blood to the rest of the body. Patients with aortic stenosis and symptoms who do not undergo aortic valve replacement face up to a 50 percent mortality rate at three years from symptom onset. Thus, aortic valve replacement is truly a life-saving procedure.

Posted in Announcements, Newsmakers, Press Releases0 Comments